MedPath

Low Concentration Atropine for Myopia Progression in School Children

Not Applicable
Completed
Conditions
Myopia Progression
Interventions
Registration Number
NCT02130167
Lead Sponsor
Chang Gung Memorial Hospital
Brief Summary

Myopia is the leading cause of blindness in Taiwan. The younger children with myopia, the higher risk of high myopia in later life and complications such as retinal detachment and maculopathy will occur. We have reported the low concentration of atropine (0.05%) with the effect on retarding the myopia progression. Recently the 0.01% atropine was also reported effective and with less visual side effects such as mydriasis. The aim of this study is to compare the efficacy in controlling myopia progression and visual side effects of 2 low concentration of atropine(0.05% vs 0.01%) in children aged 6-12 years with myopia of at least -0.5 diopters (D) and astigmatism of -1.50 D or less.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
60
Inclusion Criteria

Myopia of at least -0.5 diopters (D) and astigmatism of -1.50 D or less.

Exclusion Criteria

strabismus, amblyopia. cataract, glaucoma or any ocular diseases ocular surgery history systemic diseases (ex. asthma, heart disease...)

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
0.05% AtropineAtropine-
0.01% AtropineAtropine-
Primary Outcome Measures
NameTimeMethod
Cycloplegic spherical refraction change1 year

Cycloplegic spherical refraction change is the main indicator of the myopia progression.

Secondary Outcome Measures
NameTimeMethod
Axial length change1 year

Axial length change is another indicator of the myopia progression.Using non-contact biometry. unit: millimeter(mm)

Trial Locations

Locations (1)

Kaohsiung Chang Gung Memorial Hospital

🇨🇳

Kaohsiung, Taiwan

© Copyright 2025. All Rights Reserved by MedPath